[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354450-105":59,"doc-detail-354450-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","development-of-a-novel-urine-based-high-risk-human-papillomavirus-polymerase-chain-reaction-test-to-predict-cervical-intraepithelial-neoplasia-abnormalities-associated-with-cervical-cancer","Development of a novel, urine-based high-risk human papillomavirus polymerase chain reaction test to predict cervical intraepithelial neoplasia abnormalities associated with cervical cancer","","This study evaluated and optimized a novel urine-based high-risk human papillomavirus (hrHPV) polymerase chain reaction (PCR) workflow to detect 14 hrHPV genotypes linked to cervical intraepithelial neoplasia (CIN) abnormalities for cervical cancer screening. In cohort 1, 82 women with confirmed CIN2+ provided paired urine and cervical brush samples before treatment. In cohort 2, 983 women were analyzed to optimize cycle threshold cut-offs. The urine test achieved 92.7% sensitivity for CIN2+ and 93.9% for CIN3+ in cohort 1. Adjustable Ct thresholds supported balanced or maximum-sensitivity performance while preserving HPV16/18 cut-offs.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-a-novel-urine-based-high-risk-human-papillomavirus-polymerase-chain-reaction-test-to-predict-cervical-intraepithelial-neoplasia-abnormalities-associated-with-cervical-cancer/354450/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-a-novel-urine-based-high-risk-human-papillomavirus-polymerase-chain-reaction-test-to-predict-cervical-intraepithelial-neoplasia-abnormalities-associated-with-cervical-cancer/354450.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the urine-based hrHPV PCR test aim to detect?","Question",{"text":113,"@type":114},"It detects 14 hrHPV genotypes associated with cervical intraepithelial neoplasia (CIN) abnormalities used for cervical cancer screening, including individual HPV16 and HPV18 typing.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were Ct cut-offs optimized in the study?",{"text":118,"@type":114},"Cycle threshold (Ct) cut-offs for the 12 other hrHPV channels were varied from 28.0 to 38.0, while HPV16/18 Ct cut-offs were kept at 38.0 in the optimization cohort.",{"name":120,"@type":111,"acceptedAnswer":121},"What diagnostic performance did the urine test achieve?",{"text":122,"@type":114},"In cohort 1, the urine test showed 92.7% sensitivity for CIN2+ and 93.9% for CIN3+, exceeding cervical brush sensitivities reported as 78.1% and 90.9% respectively.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354450,1790467476,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","| Clinical Microbiology | Research Article  \nDevelopment of a novel, urine-based high-risk human papillomavirus polymerase chain reaction test to predict cervical intraepithelial neoplasia abnormalities associated with cervical cancer  \nVasu Saini,1 Zhengyang Guo,1 Jinwen Yu,1 Di Wu,2 Hui Du,2 Peng Yin,1 Garrett Lee Mosley,1 Wenkui Dai,2 Ricky Yin To Chiu1 AUTHOR AFFILIATIONS See affiliation list on p. 11.  \nABSTRACT This study evaluated and optimized a novel urine-based workflow using high-risk human papillomavirus (hrHPV) polymerase chain reaction (PCR) test to detect 14 hrHPV genotypes linked to cervical intraepithelial neoplasia (CIN) abnormalities for cervical cancer screening. In cohort 1 for clinical feasibility, 82 women with confirmed CIN2+ abnormalities provided paired urine and cervical brush samples before treatment. Urine was tested with the novel hrHPV workflow, and cervical brushes with the Cobas HPV Test (Roche) . For Ct cut-off optimization in cohort 2, urine samples from 983 women in a primary screening, triage, and follow-up program were analyzed, optimizing CIN2+ and CIN3+ sensitivity and specificity by varying the 12-other hrHPV channel Ct cut-off from 28.0 to 38.0, while maintaining HPV16/18 Ct cut-offs at 38.0. In cohort 1, the urine hrHPV test showed 92.7% sensitivity for CIN2+ and 93.9% for CIN3+, exceeding cervical brush sensitivities of 78.1% and 90.9%, respectively. In cohort 2, the 12-other hrHPV Ct altered CIN2+ sensitivity from 76.6% to 93.6% and specificity from 83.1% to 75% . ROC analysis identified optimal cut-offs at 32.76 for CIN2+ and 30.47 for CIN3+. The proposed cut-offs are HPV16/18 at 38.0, and 12 other hrHPV at 33.0 for maximum sensitivity (93.62% CIN2+, 90.91% CIN3+) or at 30.5 for balanced performance (89.36% CIN2+ sensitivity, 80% specificity) . The urine-based hrHPV test uses 40 mL of urine collected using a standard urine collection device, and demonstrated high sensitivity for CIN2+ prediction. Adjustable Ct thresholds allow tailored performance optimization, thereby enhancing accessibility, adherence, and early cervical cancer detection across diverse clinical settings.  \nIMPORTANCE A novel urine-based high-risk human papillomavirus (hrHPV) polymerase chain reaction test was developed to detect 14 hrHPV genotypes, including individual HPV16 and HPV18 typing, associated with cervical cancer progression. By employing a liquid-liquid separation method to extract DNA from large-volume (40 mL) pot-collected urine samples, the test demonstrated sensitivities of 92.7% for cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and 93.9% for CIN3+ . Optimization of cycle threshold cut-offs yielded 93% sensitivity and 77% specificity for predicting CIN2+ in an enriched population. It can enhance accessibility, compliance, and early detection across diverse clinical settings.  \nKEYWORDS urine-based HPV testing, self-sampling, cervical cancer screening, cervical intraepithelial neoplasia (CIN) abnormalities, high-risk HPV (hrHPV), qPCR assay, liquid-liquid extraction  \nEditor Ana Cabrera, London Health Sciences Centre, London, Ontario, Canada  \nAddress correspondence to Ricky Yin To Chiu, [ricky.chiu@phasesci.com](ricky.chiu@phasesci.com).  \nV. S., Z. G., J.Y., P.Y., G. L. M., and R.Y.T. C. all have an equity interest and employment with Phase Scientific  \nO ver 99.7% of cervical cancer cases are linked to persistent high-risk human  \npapillomavirus (hrHPV) infection, with high-risk types 16 and 18 responsible for approximately 70% of cases (1, 2) . In addition to vaccination, routine screening to identify and quickly treat pre-cancerous lesions, typically through cryotherapy or thermal ablation, is an effective approach for managing disease progression within a population. According to the World Health Organization, HPV DNA-based screening is a more effective strategy than traditional cytology-based methods, such as Pap smear, due to its ability to detect the oncovirus prior to cellu","cbCailWxHGzNvgta","https://ap.wps.com/l/cbCailWxHGzNvgta","pdf",784865,13,"English","# Abstract\n## Cohort 1 clinical feasibility\n## Cohort 2 Ct cut-off optimization\n## Performance metrics and ROC-defined cut-offs\n## Test workflow and implications","[{\"question\":\"What does the urine-based hrHPV PCR test aim to detect?\",\"answer\":\"It detects 14 hrHPV genotypes associated with cervical intraepithelial neoplasia (CIN) abnormalities used for cervical cancer screening, including individual HPV16 and HPV18 typing.\"},{\"question\":\"How were Ct cut-offs optimized in the study?\",\"answer\":\"Cycle threshold (Ct) cut-offs for the 12 other hrHPV channels were varied from 28.0 to 38.0, while HPV16/18 Ct cut-offs were kept at 38.0 in the optimization cohort.\"},{\"question\":\"What diagnostic performance did the urine test achieve?\",\"answer\":\"In cohort 1, the urine test showed 92.7% sensitivity for CIN2+ and 93.9% for CIN3+, exceeding cervical brush sensitivities reported as 78.1% and 90.9% respectively.\"}]","Development of a novel, urine-based high-risk human papillomavirus polymerase chain reaction test to predict cervical intraepithelial neoplasia abnormalities associated with cervical cancer | PDF",1790110692,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e56fd2061bacf90b831fe6157dae095c.webp",983,1315,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ebe93be66c43091da90877893af7090.webp",982,1314,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d81193cec10ab1325166f52eebd3653.webp",981,1312,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/265f7655a569a0f2e7cdbabf3392170f.webp",980,1311]